



PATENT

Customer No. 22,852

Attorney Docket No. 08702.0020-00000

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

VELDMAN et al.

Application No.: 10/688,925

Filed: October 21, 2003

For: NEUTRALIZING ANTIBODIES
AGAINST GDF-8 AND USES
THEREFOR

)
)
) Group Art Unit: 1645

)
) Examiner: Not yet assigned

)
)
) Confirmation No.: 2555

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application. The documents listed in this Information Disclosure Statement were cited in the PCT International Search Report in the corresponding international application, which was mailed on June 1, 2004, less than 30 days from this submission. Two of the documents cited in the International Search Report have previously been submitted to the Examiner in this case. Additionally, Applicants believe that the International Search Report may contain a typographical error and that document WO 03/037248 should be WO 03/027248; however, in an abundance of caution, both documents are being submitted with this Information Disclosure Statement.

Copies of the listed documents, including any copending patent applications, are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,


FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: June 25, 2004

By: Rebecca M. McNeill
Rebecca M. McNeill
Reg. No. 43,796

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08702.0020-00000	Appln. No.	10/688,925
Applicant	VELDMAN et al.		
Filing Date	October 21, 2003	Group:	1645



U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
		WO 94/21681	29-SEPT-1994	PCT	C07K	13/00	
		WO 99/56768	11-NOV-1999	PCT	A61K	38/18	
		WO 03/037248	08-MAY-2003	PCT	A61K		
		WO 03/027248	03-APR-2003	PCT	C12N		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	International Search Report, PCT/IB 03/04745, mailed June 1, 2004
	Hill, J. et al., "The Mytostatin Propeptide and the Follistatin-related Gene Are Inhibitory Binding Proteins of Myostatin in Normal Serum," <i>J. Biol. Chem.</i> 277:40735-40741 (2002)

Examiner	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449 Patent and Trademark Office - U.S. Department of Commerce	

did not receiving these WPLrs)